Casualty Of Change? Innovent/Lilly’s Chinese PD-1 Inhibitor Sintilimab Falls Hard At US FDA Panel

 
• By Sue Sutter
Step backwards
Single-country submissions are 'a step backward' in efforts to promote clinical trial diversity and multi-regional trials, FDA's top oncology official says. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers